Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Type 1 DiabetesDiabetic Kidney DiseaseDiabetes ComplicationsDiabetic NephropathiesAutoimmune Diabetes
Interventions
DRUG

Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.

DRUG

Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.

Trial Locations (1)

80045

RECRUITING

Children's Hospital Colorado, Aurora

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Colorado, Denver

OTHER